Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery von Ruggeri, Bruce A., Camp, Faye, Miknyoczki, Sheila

Volltext

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) von Marzec, Michal, Zhang, Qian, Goradia, Ami, Raghunath, Puthiyaveettil N, Liu, Xiaobin, Paessler, Michele, Wang, Hong Yi, Wysocka, Maria, Cheng, Mangeng, Ruggeri, Bruce A, Wasik, Mariusz A

Volltext

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models von Liu, Phillip C. C., Koblish, Holly, Wu, Liangxing, Bowman, Kevin, Diamond, Sharon, DiMatteo, Darlise, Zhang, Yue, Hansbury, Michael, Rupar, Mark, Wen, Xiaoming, Collier, Paul, Feldman, Patricia, Klabe, Ronald, Burke, Krista A., Soloviev, Maxim, Gardiner, Christine, He, Xin, Volgina, Alla, Covington, Maryanne, Ruggeri, Bruce, Wynn, Richard, Burn, Timothy C., Scherle, Peggy, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Hollis, Gregory

Volltext

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK) von Ott, Gregory R, Cheng, Mangeng, Learn, Keith S, Wagner, Jason, Gingrich, Diane E, Lisko, Joseph G, Curry, Matthew, Mesaros, Eugen F, Ghose, Arup K, Quail, Matthew R, Wan, Weihua, Lu, Lihui, Dobrzanski, Pawel, Albom, Mark S, Angeles, Thelma S, Wells-Knecht, Kevin, Huang, Zeqi, Aimone, Lisa D, Bruckheimer, Elizabeth, Anderson, Nathan, Friedman, Jay, Fernandez, Sandra V, Ator, Mark A, Ruggeri, Bruce A, Dorsey, Bruce D

Volltext

Animal models of human disease: Challenges in enabling translation von McGonigle, Paul, Ruggeri, Bruce

Volltext

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis von Stump, Kristine L, Lu, Lily D, Dobrzanski, Pawel, Serdikoff, Cynthia, Gingrich, Diane E, Dugan, Ben J, Angeles, Thelma S, Albom, Mark S, Ator, Mark A, Dorsey, Bruce D, Ruggeri, Bruce A, Seavey, Matthew M

Volltext

PAX genes: Roles in development, pathophysiology, and cancer von Lang, Deborah, Powell, Sara K., Plummer, Rebecca S., Young, Kacey P., Ruggeri, Bruce A.

Volltext

Cancer 2021: New therapeutic approaches for the treatment of cancer — building on advances in cancer biology and the molecular genetics of cancer von Ruggeri, Bruce

Volltext

Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2 von Lu, Lily D, Stump, Kristine L, Wallace, Nate H, Dobrzanski, Pawel, Serdikoff, Cynthia, Gingrich, Diane E, Dugan, Benjamin J, Angeles, Thelma S, Albom, Mark S, Mason, Jennifer L, Ator, Mark A, Dorsey, Bruce D, Ruggeri, Bruce A, Seavey, Matthew M

Volltext

Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes von Piva, Roberto, Pellegrino, Elisa, Mattioli, Michela, Agnelli, Luca, Lombardi, Luigia, Boccalatte, Francesco, Costa, Giulia, Ruggeri, Bruce A, Cheng, Mangeng, Chiarle, Roberto, Palestro, Giorgio, Neri, Antonino, Inghirami, Giorgio

Volltext

Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells von Ito, Koichi, Thodima, Venkat, Carter, Jack, Bhagwat, Neha, Sivakumar, Monisha, Grego, Alexander, Rager, Joseph, Terai, Mizue, Sato, Takami, Abdel-Wahab, Omar, Ruggeri, Bruce, Scherle, Peggy, Vaddi, Kris

Volltext

The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells von Salem, Israa, Alsalahi, Manal, Chervoneva, Inna, Aburto, Lucy D, Addya, Sankar, Ott, Gregory R, Ruggeri, Bruce A, Cristofanilli, Massimo, Fernandez, Sandra V

Volltext

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE von Seavey, Matthew M., Lu, Lily D., Stump, Kristine L., Wallace, Nate H., Ruggeri, Bruce A.

Volltext

Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer von Seavey, Matthew M, Lu, Lily D, Stump, Kristine L, Wallace, Nate H, Hockeimer, William, O'Kane, Teresa M, Ruggeri, Bruce A, Dobrzanski, Pawel

Volltext

Design, Synthesis, and Biological Evaluation of Sulfonyl Acrylonitriles as Novel Inhibitors of Cancer Metastasis and Spread von Shen, Yi, Zificsak, Craig A, Shea, Jill E, Lao, Xuegang, Bollt, Oana, Li, Xiufen, Lisko, Joseph G, Theroff, Jay P, Scaife, Courtney L, Ator, Mark A, Ruggeri, Bruce A, Dorsey, Bruce D, Kuwada, Scott K

Volltext

Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment von Mirza, Amar N, Fry, Micah A, Urman, Nicole M, Atwood, Scott X, Roffey, Jon, Ott, Gregory R, Chen, Bin, Lee, Alex, Brown, Alexander S, Aasi, Sumaira Z, Hollmig, Tyler, Ator, Mark A, Dorsey, Bruce D, Ruggeri, Bruce R, Zificsak, Craig A, Sirota, Marina, Tang, Jean Y, Butte, Atul, Epstein, Ervin, Sarin, Kavita Y, Oro, Anthony E

Volltext

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers von Cheng, Mangeng, Quail, Matthew R, Gingrich, Diane E, Ott, Gregory R, Lu, Lihui, Wan, Weihua, Albom, Mark S, Angeles, Thelma S, Aimone, Lisa D, Cristofani, Flavio, Machiorlatti, Rodolfo, Abele, Cristina, Ator, Mark A, Dorsey, Bruce D, Inghirami, Giorgio, Ruggeri, Bruce A

Volltext

Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer von Dorsey, Bruce D, Iqbal, Mohamed, Chatterjee, Sankar, Menta, Ernesto, Bernardini, Raffaella, Bernareggi, Alberto, Cassarà, Paolo G, D’Arasmo, Germano, Ferretti, Edmondo, De Munari, Sergio, Oliva, Ambrogio, Pezzoni, Gabriella, Allievi, Cecilia, Strepponi, Ivan, Ruggeri, Bruce, Ator, Mark A, Williams, Michael, Mallamo, John P

Volltext

A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779 von Dugan, Benjamin J, Gingrich, Diane E, Mesaros, Eugen F, Milkiewicz, Karen L, Curry, Matthew A, Zulli, Allison L, Dobrzanski, Pawel, Serdikoff, Cynthia, Jan, Mahfuza, Angeles, Thelma S, Albom, Mark S, Mason, Jennifer L, Aimone, Lisa D, Meyer, Sheryl L, Huang, Zeqi, Wells-Knecht, Kevin J, Ator, Mark A, Ruggeri, Bruce A, Dorsey, Bruce D

Volltext

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo von Levis, Mark, Allebach, Jeffrey, Tse, Kam-Fai, Zheng, Rui, Baldwin, Brenda R., Smith, B. Douglas, Jones-Bolin, Susan, Ruggeri, Bruce, Dionne, Craig, Small, Donald

Volltext